Scale -


  • Revenue is 58462 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 11 %
  • Ebitda is 19703 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 15 %
  • PAT is 11565 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 36 %
  • PBT is 4108 Rs Cr; in Top Quartile; 5 Year CAGR is 36 %
  • Quarterly Revenue is 15184 Rs Cr; in Top Quartile

Profitability -


  • PBDIT Margin is 33.7 %; Continuous Growth over 3 years; in Top Quartile
  • PAT Margin is 19.78 %; in Top Quartile; 5 Year CAGR is 22 %
  • Quarterly Ebitda Margin is 29 %; in Top Quartile
  • Quarterly Profit margin is 19 %; in Top Quartile

Return -


  • ROA is 10.55 %; 5 Year CAGR is 23 %
  • ROE is 13.73 %; 5 Year CAGR is 19 %

Efficiency -


  • Inventory Turnover Ratio is 5.38; Continuous Growth over 3 years; 5 Year CAGR is 62 %
  • Current Ratio is 2.82; in Top Quartile
  • Quick Ratio is 2.32; in Top Quartile
  • Operating cash flow is 12419 Rs Cr; in Top Quartile

Solvancy -


  • Long term Debt is 31.26 Rs Cr; 5 Year CAGR is -39 %; Annual Growth is 1140 %; Continuous Growth over 3 years
  • Debt/Equity is 0.05; Annual Growth is 67 %; 5 Year CAGR is 26 %
  • Total Debt is 4082 Rs Cr; Annual Growth is 118 %; in Top Quartile; 5 Year CAGR is 45 %
  • Contingent Liabilities is 5557 Rs Cr; in Top Quartile

Quality -


  • Exceptional Items/PBT is -9 %; Annual Decline is -75 %; Continuous Decline over 3 years; in Bottom Quartile
  • Operating cashflow/ebitda is 63 %; Annual Decline is -23 %; Continuous Decline over 3 years
  • Current Tax/PAT is 36 %; Annual Growth is 20 %; Continuous Growth over 3 years; 5 Year CAGR is 37 %
  • Change in Inventories/Total Expenses is 1 %; Annual Growth is 108 %; in Top Quartile
  • Other Expenses/Total Expenses is 40 %; in Top Quartile
  • Operating cashflow/PAT is 107 %; 5 Year CAGR is -20 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
EXCLUSIVE: India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India's Sun Pharma posts lower quarterly profit on one-time acquisition-related charge
Q2 Results Today, October 30: Reliance Industries, Jio Platforms, Sun Pharma, BEL, Indian Oil among 200+ companies announcing earnings
Q2 Results, Oct 30: Reliance Industries, Jio Platforms, BEL, IOCL, Varun Beverages, Bank of Baroda, NTPC Green, others to post earnings
Reliance Industries, Dixon Technologies, and 8 Other Stocks Set to Announce Q2 Results Today
Sun Pharma Q2 results: Net profit falls 36% to Rs 1,989 cr on one-time hit, revenue up 12%; stock jumps
Sun Pharma Q2 results: Net profit falls 36% to Rs 1,989 crore, hit by one-time loss; revenue at Rs 16,199 crore
Sun Pharma shares extend four-day rally after USFDA approval for ILUMYA in arthritis patients
Sun Pharma shares gain even as Q2 profit slips 36% YoY; here's why
Sun Pharma stock in focus after US FDA approves drug for psoriatic arthritis
Sun Pharma's ILUMYA Gets US Nod for Psoriatic Arthritis Treatment; Shares Up 1.5%
Sun Pharma's profit falls on Organon deal charge; specialty drug sales remain strong
Sun Pharma's Q2 profit drops 36 pc to Rs 1,989 crore on one-time loss
Sun Pharma completes $11.75bn financing syndication for Organon acquisition
Sun Pharma down 2%, stock hits over 5-month low
Healthcare, pharma shares extend decline for 3rd day; Sun Pharma, Dr. Reddy's among top losers